Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Comparable remission rates in therapy-related and myelodysplasia-related Acute Myeloid Leukemia (AML) versus de novo AML treated with azacitidine and venetoclax: A contemporary real-world study.

Zahra AlHaj Issa, Cristiano Machado De Freitas, Aarya Murali, Akhil Rajendra, Dawn Maze, Aniket Banker, Steven Chan, Marta Davidson, Aaron Schimmer, Andre Schuh, Hassan Sibai, Karen W.L. Yee, Mark Minden, Vikas Gupta, Maria Perusini, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 3390.

https://doi.org/10.1182/blood-2025-3390

Published: 2025

Journal Articles

Extramedullary disease in AML: A high-risk feature beyond ELN 2022 classification

Yael Morgenstern, Claire Andrews, Eshetu Atenafu, Steven Chan, Vikas Gupta, Mark Minden, Dawn Maze, Aaron Schimmer, Andre Schuh, Karen W.L. Yee, Hassan Sibai

Blood (2025) 146 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2025-3388

Published: 2025

Journal Articles

Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax

Aarya Murali, Zahra AlHaj Issa, Cristiano Machado De Freitas, Akhil Rajendra, Marta Davidson, Aniket Bankar, Hassan Sibai, Maria Perusini, Steven Chan, Aaron Schimmer, Mark Minden, Karen W.L. Yee, Andre Schuh, Vikas Gupta, Dawn Maze, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 3508.

https://doi.org/10.1182/blood-2025-3508

Published: 2025

Journal Articles

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

Josephine Anne Lucero, Maria Perusini, Aniket Bankar, Marta Davidson, Guillaume Richard-Carpentier, Aaron Schimmer, Andre Schuh, Dawn Maze, Karen W.L. Yee, Mark Minden, Steven Chan, Jose-Mario Capo-Chichi, Vikas Gupta, Hassan Sibai, Anne Tierens, Dennis Kim

Blood (2025) 146 (Supplement 1): 7051.

https://doi.org/10.1182/blood-2025-7051

Published: 2025

Journal Articles

Real-world evidence evaluation of the safety and efficacy of intensive chemotherapy with or without gemtuzumab ozogamicin (GO) in patients with newly diagnosed Acute Myeloid Leukemia (AML) and favorable or intermediate risk cytogenetics

Elizabeth Herrity, Dawn Maze, Marta Davidson, Aniket Bankar, Maria Perusini, Hassan Sibai, Steven Chan, Aaron Schimmer, Mark Minden, Karen W.L. Yee, Andre Schuh, Vikas Gupta, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 5240.

https://doi.org/10.1182/blood-2025-5240

Published: 2025

Journal Articles

Prognostic impact of molecular genetic and cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with azacitidine and venetoclax: A real-world cohort study

Cristiano Machado De Freitas, Aarya Murali, Zahra AlHaj Issa, Aniket Bankar, Hassan Sibai, Maria Perusini, Aaron Schimmer, Mark Minden, Steven Chan, Karen W.L. Yee, Andre Schuh, Vikas Gupta, Dawn Maze, Marta Davidson, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 4776.

https://doi.org/10.1182/blood-2025-4776

Published: 2025

Journal Articles

Mixed phenotype acute leukemia: Clinical characteristics and real-world outcomes

Ana Patiño, Hong Chang, Mark Turingan, Aniket Bankar, Jonathan Wei, Marta Davidson, Guillaume Richard-Carpentier, Mark Minden, Andre Schuh, Karen W.L. Yee, Vikas Gupta, Dawn Maze, Steven Chan, Aaron Schimmer, Claire Andrews, Hassan Sibai, Maria Perusini

Blood (2025) 146 (Supplement 1): 3330.

https://doi.org/10.1182/blood-2025-3330

Published: 2025

Journal Articles

FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML

Akhil Rajendra, Dawn Maze, Aniket Bankar, Steven Chan, Marta Davidson, Vikas Gupta, Mark Minden, Maria Perusini, Guillaume Richard-Carpentier, Aaron Schimmer, Andre Schuh, Elliot Smith, Karen W.L. Yee, Hassan Sibai

Blood (2025) 146 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2025-1672

Published: 2025

Journal Articles

Clinical Outcomes in De Novo Versus Secondary NPM1 -Mutated AML

Elliot C. Smith, Eshetu G. Atenafu, Aniket Bankar, Steven M. Chan, Marta B. Davidson, Vikas Gupta, Mark D. Minden, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Dawn Maze

Blood (2022) 140 (Supplement 1): 8952–8953.

https://doi.org/10.1182/blood-2022-166939

Published: 2022

Journal Articles

Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience

Salman Alharbi, Maria Agustina Perusini, Sita Bhella, Mark D. Minden, Dawn Maze, Vikas Gupta, Aaron D. Schimmer, Andre C. Schuh, Karen Yee, Steven M. Chan, Aniket Bankar, Marta B. Davidson, Guillaume Richard-Carpentier, Jad Sibai, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3187–3188.

https://doi.org/10.1182/blood-2022-168662

Published: 2022

Journal Articles

Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis

Jessie J.F. Medeiros, Andy G.X. Zeng, Michelle Chan-Seng-Yue, Tristan Woo, Jessica L McLeod, Andrea Arruda, Hubert Tsui, Burhan Goraya, Jaime O. Claudio, Jenny M. Ho, James A. Kennedy, Dawn Maze, Hassan Sibai, Mark D. Minden, Jean C.Y. Wang, John E. Dick, Vikas Gupta

Blood (2022) 140 (Supplement 1): 9681–9682.

https://doi.org/10.1182/blood-2022-163722

Published: 2022

Journal Articles

Comparison of Clinical Outcomes between Transplant and Non-Transplant Therapies in Myelofibrosis Following Failure of First-Line JAK-Inhibitor

James T. England, Eshetu G. Atenafu, James A. Kennedy, Burhan Goraya, Verna Cheung, Taylor Nye, Karine Gauthier, Marta B. Davidson, Aniket Bankar, Hassan Sibai, Dawn Maze, Auro Viswabandya, Vikas Gupta

Blood (2022) 140 (Supplement 1): 9724–9725.

https://doi.org/10.1182/blood-2022-165272

Published: 2022

Journal Articles

Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers

Josephine Anne Lucero, Brayan Merchán, Osamah Jamal S. Jarallah, Aniket Bankar, Steven M. Chan, Marta B. Davidson, Vikas Gupta, Dawn Maze, Mark D. Minden, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Karen Yee, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3166–3168.

https://doi.org/10.1182/blood-2022-168488

Published: 2022

Journal Articles

Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol

Maria Agustina Perusini, Jad Sibai, Eshetu G. Atenafu, Aniket Bankar, Mark D. Minden, Vikas Gupta, Dawn Maze, Marta B. Davidson, Steven M. Chan, Aaron D. Schimmer, Guillaume Richard-Carpentier, Josephine Anne Lucero, Claire Andrews, Dennis Dong Hwan Kim, Karen Yee, Andre C. Schuh, Hassan Sibai

Blood (2022) 140 (Supplement 1): 6039–6041.

https://doi.org/10.1182/blood-2022-169406

Published: 2022

Journal Articles

Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy

Kenny Tang, Dawn Maze, Karen Yee, Hassan Sibai, Marta B. Davidson, Steven M. Chan, Aaron D. Schimmer, Andre C. Schuh, Aniket Bankar, Guillaume Richard-Carpentier, Anne Tierens, Mark D. Minden, Vikas Gupta, Jeffrey H. Lipton, Dennis Kim

Blood (2022) 140 (Supplement 1): 9608–9610.

https://doi.org/10.1182/blood-2022-166416

Published: 2022

Journal Articles

The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy

Blood (2022) 140 (Supplement 1): 9122–9124.

https://doi.org/10.1182/blood-2022-171107

Published: 2022

Journal Articles

Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up

Maria Agustina Perusini, Eshetu G. Atenafu, Aniket Bankar, Vikas Gupta, Mark D. Minden, Jad Sibai, Dawn Maze, Marta B. Davidson, Steven M. Chan, Fernando Binder, Guillaume Richard-Carpentier, Salman Alharbi, Claire Andrews, Karen Yee, Andre C. Schuh, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3176–3177.

https://doi.org/10.1182/blood-2022-170121

Published: 2022

Journal Articles

Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

Fatima M Khadadah, Claire Andrews, Eshetu G. Atenafu, Andre C. Schuh, Dawn Maze, Karen Yee, Osamah Jamal S. Jarallah, Mark D. Minden, Aaron D. Schimmer, Steven M. Chan, Vikas Gupta, Dennis Dong Hwan Kim, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3169–3171.

https://doi.org/10.1182/blood-2022-169342

Published: 2022

Journal Articles

Pregnancy Management and Outcomes in Patients with Myeloproliferative Neoplasms

Iyad Arusi, Vikas Gupta, Ann Kinga Malinowski, Nadine Shehata, Dawn Maze

Blood (2021) 138 (Supplement 1): 4615.

https://doi.org/10.1182/blood-2021-153887

Published: 2021

Journal Articles

Enasidenib in Combination with Venetoclax in IDH2 -Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial

Steven M Chan, Charina Cameron, Severine Cathelin, Vikas Gupta, Dawn Maze, Mark D. Minden, Tracy Murphy, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Courtney D. DiNardo, Caroline J McNamara

Blood (2021) 138 (Supplement 1): 1263.

https://doi.org/10.1182/blood-2021-153660

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Comparable remission rates in therapy-related and myelodysplasia-related Acute Myeloid Leukemia (AML) versus de novo AML treated with azacitidine and venetoclax: A contemporary real-world study.

Extramedullary disease in AML: A high-risk feature beyond ELN 2022 classification

Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

Real-world evidence evaluation of the safety and efficacy of intensive chemotherapy with or without gemtuzumab ozogamicin (GO) in patients with newly diagnosed Acute Myeloid Leukemia (AML) and favorable or intermediate risk cytogenetics

Prognostic impact of molecular genetic and cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with azacitidine and venetoclax: A real-world cohort study

Mixed phenotype acute leukemia: Clinical characteristics and real-world outcomes

FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML

Clinical Outcomes in De Novo Versus Secondary NPM1 -Mutated AML

Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience

Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis

Comparison of Clinical Outcomes between Transplant and Non-Transplant Therapies in Myelofibrosis Following Failure of First-Line JAK-Inhibitor

Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers

Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol

Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy

The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy

Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up

Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

Pregnancy Management and Outcomes in Patients with Myeloproliferative Neoplasms

Enasidenib in Combination with Venetoclax in IDH2 -Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only